title: IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?
authors: Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, "Sant Joan" University Hospital, Universitat Rovira i Virgili, IISPV, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Reus, Spain.
authors: Luis
authors: L
authors: Masana
authors: Lipid and Vascular Risk Unit, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors: Juan
authors: J
authors: Pedro-Botet
authors: Head Lipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, Red Cardiovascular Research Network (RIC), Zaragoza, Spain. Electronic address: civeira@unizar.es.
authors: Fernando
authors: F
authors: Civeira
mesh_terms: D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood*; D002986:Clinical Trials as Topic; D015536:Down-Regulation; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D000069438:Ezetimibe / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol; D000069438:Ezetimibe
keywords: Ezetimibe; High-intensity cholesterol-lowering therapy; IMPROVE-IT